Glioma drug development benefits from emerging phase 0 and window-of-opportunity trial paradigm

Area of Science:

• Neuro-oncology
• Clinical Pharmacology
• Translational Medicine

Background:

• Glioblastoma (GBM) presents significant challenges for effective treatment due to its rarity and difficulty in treatment.
• Innovative drug discovery requires reliable early-stage signals of drug activity and efficient translation to clinical benefits.
• Accelerated drug development is crucial for rare and difficult-to-treat solid tumors.

Purpose of the Study:

• To review current evidence on the window-of-opportunity (WOO) trial design in glioma.
• To advocate for the WOO design as a standard paradigm in new drug development for glioma.
• To highlight the potential of WOO designs to improve trial quality and reduce costs.

Main Methods:

• Review of existing literature on window-of-opportunity and Phase 0 trials in glioma.
• Analysis of challenges in implementing WOO designs, including sample acquisition and biomarker identification.
• Encapsulation of evidence supporting the efficacy of WOO designs in early drug development.

Main Results:

• WOO designs aim to identify and eliminate ineffective therapies early, enhancing overall trial quality.
• Implementation challenges include pre-treatment sample acquisition, methodological platforms, and biostatistical pipelines.
• Novel biomarkers integrating clinical and multi-omics data are needed for predicting long-term drug responses.

Conclusions:

• The window-of-opportunity design offers a promising approach for accelerating drug development in glioma.
• Addressing implementation challenges is key to widespread adoption of this trial design.
• Standardizing WOO designs can foster more efficient drug development for rare and difficult-to-treat cancers.